The Patent Trial and Appeal Board has issued its Final Written Decision in IPR2025-00070, bringing the inter partes review to its merits-stage conclusion and giving practitioners another look at how the Board is applying patentability standards in contested post-grant proceedings. View full case on Docket Alarm

Because a Final Written Decision is the PTAB’s definitive resolution of the challenged claims and grounds that were instituted, the opinion matters well beyond the immediate dispute.

A federal judge in Boston has again blocked key provisions of President Donald Trump’s executive order aimed at expanding the federal government’s role in election administration, marking another significant judicial check on the administration’s effort to reshape voting rules ahead of the 2026 midterms.

U.S. District Judge Indira Talwani, of the U.S. District Court in Massachusetts, ruled against provisions that would have helped create a federal voter list and more directly inserted federal authority into functions traditionally handled by states.

The Eleventh Circuit’s August 7, 2026 filing in Opinion, No. 25-13883, is now available on Docket Alarm. At the time of writing, the key takeaway for practitioners is the release of the appellate disposition itself and the need to review the opinion closely for its treatment of the issues on appeal, procedural posture, and any statements that may affect future briefing strategy in the circuit.

Because appellate opinions can turn on narrow procedural grounds as often as on merits questions, lawyers should focus first on three things: what judgment the panel entered, whether the court affirmed, reversed, vacated, or remanded; the standard of review it applied; and whether the holding is expressly limited to the facts before it or framed in broader doctrinal terms.

The Department of Justice’s recent press-release activity points to a notable trend for legal professionals: federal enforcement remains active on multiple fronts at once. In late July and early August, DOJ announcements reflected a steady mix of healthcare-fraud resolutions, terrorism-related charges, and other criminal prosecutions, underscoring that the government is continuing to deploy both its criminal and civil tools aggressively across industries and fact patterns.

That matters because the news is not just about any single headline-making case.

A new post-grant review at the Patent Trial and Appeal Board could be worth close attention for companies operating in the dental implant and medical device space. In PGR2026-00070, filed on August 11, 2026, the proceeding is captioned Straumann USA, LLC, signaling a challenge to a recently issued patent associated with one of the best-known names in dental technology.

At this stage, the docket entry identifies the matter by party name and PTAB number, but practitioners will want to watch for the petition and related filings to clarify the specific patent claims at issue, the identity of the petitioner, and the precise invalidity theories being advanced.

The FTC has secured what it says is the largest civil penalty ever obtained for a Hart-Scott-Rodino filing failure: a combined $12 million settlement with Edwards Lifesciences and Genesis MedTech over the acquisition of JC Medical. According to the agency, the companies structured the transaction to avoid premerger notification and waiting-period requirements under the HSR Act, prompting an enforcement action filed in the U.S. District Court for the District of Columbia by the DOJ on the FTC’s behalf.

That headline number matters.

Meta Platforms, Inc. has launched a new inter partes review at the Patent Trial and Appeal Board, filing IPR2026-00420 on August 7, 2026. The petition opens another closely watched PTAB contest involving a major technology company and underscores how frequently the Board remains central to high-stakes patent strategy.

At this early stage, the docket identifies the proceeding by petitioner name—Meta Platforms, Inc.—but the publicly available case caption information does not yet disclose the full patent details or the patent owner in the materials summarized here.

The Justice Department has authorized a $400 million settlement to resolve litigation brought by the Alaska Native Tribal Health Consortium over contract support costs under the Indian Self-Determination and Education Assistance Act (ISDEAA). The dispute centered on the federal government’s obligation to fund the overhead and administrative expenses tribal entities incur when they assume responsibility for delivering healthcare services that the government would otherwise provide.

The settlement is notable not just for its size, but for what it says about the federal government’s continuing exposure in ISDEAA funding disputes.

I’m missing the underlying news story you want covered. To write a 300–500 word Docket Alarm-style post that is specific, accurate, and useful to litigators and in-house teams, I need at least one of the following:

• the name of the case, company, court, judge, or agency action,
• a short description of the legal news event,
• any Docket Alarm case links you want woven in, or
• the 6–8 items from the last 24–48 hours you want prioritized.

Once you send that, I can turn it around in the exact requested format:

• concise, story-specific title,
• HTML-only body,
• 300–500 words,
• clear explanation of the legal significance, and
• practical takeaways for litigators, in-house counsel, and compliance teams.

If helpful, paste the story prompt in any of these formats:

• Case: Plaintiff v. Defendant, court, docket number
• News event: one- or two-sentence summary
• Docket Alarm links: 1–2 URLs to weave in naturally
• Time window: “last 24 hours” or “last 48 hours”

Send the story details and I’ll draft the finished post immediately.

Meta Platforms, Inc. has launched a new inter partes review at the Patent Trial and Appeal Board in IPR2026-00426, filed on August 5, 2026.

A newly filed motion in the Ninth Circuit, No. 3 Motion to Dismiss in case 26-5041, puts a familiar but consequential appellate issue front and center: whether the appeal should proceed at all. Appellees Joseph Taylor, Mick Cleary, Jennifer [as listed on the docket], and others filed the motion on August 7, 2026, asking the court to terminate the appeal at the threshold rather than reach the merits.

At this stage, a motion to dismiss in the court of appeals typically targets a defect in appellate jurisdiction or a serious procedural flaw.

Tuesday’s legal news cycle delivered a familiar but important message for practitioners: the biggest developments are no longer confined to blockbuster merits rulings. Instead, the day’s most significant events cut across enforcement priorities, regulatory implementation, procedural positioning, and the increasingly fast-moving intersection of agencies, courts, and corporate decision-making.

For litigators, that matters because legal risk is now being shaped as much by timing, forum, and government posture as by black-letter doctrine.

Meta Platforms, Inc. has launched a new inter partes review proceeding at the Patent Trial and Appeal Board in IPR2026-00420, filed on August 7, 2026.

A federal judge in Washington, D.C. has approved the SEC’s settlement with Elon Musk over allegations that he failed to timely disclose his early purchases of Twitter stock, but not without an unusually pointed warning. U.S. District Judge Sparkle Sooknanan signed off on the deal while stating she had “significant misgivings” and saw potential “red flags” in the resolution.

The settlement requires a trust in Musk’s name to pay $1.5 million and resolves claims tied to delayed beneficial ownership disclosures.

The Federal Trade Commission has announced what it calls a major antitrust settlement with Caremark, resolving a closely watched case against one of the country’s largest pharmacy benefit managers. Even without the full settlement details in hand, the development is important: it signals that the FTC is continuing to press competition theories aimed at the role PBMs play in drug pricing, formulary design, and pharmacy reimbursement.

For antitrust and healthcare lawyers, the significance goes well beyond a single company.